Tocqueville Asset Management L.P. Has $1.87 Million Stock Position in Lifecore Biomedical, Inc. (NASDAQ:LFCR)

Tocqueville Asset Management L.P. lowered its position in shares of Lifecore Biomedical, Inc. (NASDAQ:LFCR) by 12.4% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 351,700 shares of the company’s stock after selling 50,000 shares during the quarter. Tocqueville Asset Management L.P. owned 1.16% of Lifecore Biomedical worth $1,868,000 at the end of the most recent reporting period.

A number of other large investors have also recently bought and sold shares of LFCR. SG Americas Securities LLC acquired a new position in Lifecore Biomedical during the 1st quarter worth approximately $57,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Lifecore Biomedical in the 1st quarter valued at approximately $58,000. State Board of Administration of Florida Retirement System acquired a new stake in shares of Lifecore Biomedical in the 1st quarter valued at approximately $114,000. Oppenheimer Asset Management Inc. boosted its holdings in shares of Lifecore Biomedical by 79.9% in the 1st quarter. Oppenheimer Asset Management Inc. now owns 43,001 shares of the company’s stock valued at $228,000 after buying an additional 19,094 shares during the last quarter. Finally, Citigroup Inc. boosted its holdings in shares of Lifecore Biomedical by 2,311.6% in the 3rd quarter. Citigroup Inc. now owns 33,618 shares of the company’s stock valued at $254,000 after buying an additional 32,224 shares during the last quarter. Institutional investors and hedge funds own 83.36% of the company’s stock.

Lifecore Biomedical Trading Down 4.7 %

Shares of NASDAQ LFCR traded down $0.24 during trading hours on Friday, hitting $4.85. The company had a trading volume of 150,246 shares, compared to its average volume of 352,294. Lifecore Biomedical, Inc. has a 1-year low of $4.47 and a 1-year high of $11.45. The firm’s 50 day moving average is $5.39 and its 200-day moving average is $6.36.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.